MA29765B1 - Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire - Google Patents
Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaireInfo
- Publication number
- MA29765B1 MA29765B1 MA30723A MA30723A MA29765B1 MA 29765 B1 MA29765 B1 MA 29765B1 MA 30723 A MA30723 A MA 30723A MA 30723 A MA30723 A MA 30723A MA 29765 B1 MA29765 B1 MA 29765B1
- Authority
- MA
- Morocco
- Prior art keywords
- complementary system
- epithelial cells
- extracellular matrix
- moraxella catarrhalis
- interaction
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 2
- 241000588655 Moraxella catarrhalis Species 0.000 title abstract 2
- 210000002919 epithelial cell Anatomy 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title 1
- 102000016359 Fibronectins Human genes 0.000 abstract 2
- 108010067306 Fibronectins Proteins 0.000 abstract 2
- 108050001049 Extracellular proteins Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A61K39/1045—Moraxella
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES PROTÉINES MATRICIELLES EXTRACELLULAIRES DE MORAXELLA CATARRHALIS ET LA CAPACITÉ D'INTERAGIR AVEC DES CELLULES ÉPITHÉLIALES VIA UNE FIBRONECTINE ET UNE LAMININE ASSOCIÉE À LA CELLULE ET, ÉGALEMENT LEUR CAPACITÉ D'INHIBER LE SYSTÈME COMPLÉMENTAIRE. CES PROTÉINES EXTRACELLULAIRE CONVIENNENT POUR LA PRÉPARATION DE VACCINS. CETTE INVENTION CONCERNE DES PEPTIDES INTERAGISSANT AVEC LA FIBRONECTINE, LA LAMININE ET LE SYSTÈME COMPLÉMENTAIRE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70674505P | 2005-08-10 | 2005-08-10 | |
US70714805P | 2005-08-11 | 2005-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29765B1 true MA29765B1 (fr) | 2008-09-01 |
Family
ID=37727738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30723A MA29765B1 (fr) | 2005-08-10 | 2008-03-07 | Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire |
Country Status (15)
Country | Link |
---|---|
US (7) | US8092811B2 (fr) |
EP (4) | EP3305807B1 (fr) |
JP (2) | JP5269594B2 (fr) |
KR (1) | KR20080042865A (fr) |
AU (1) | AU2006277076B2 (fr) |
BR (1) | BRPI0614734A2 (fr) |
CA (1) | CA2618554C (fr) |
EA (1) | EA014352B1 (fr) |
ES (1) | ES2537274T3 (fr) |
IL (2) | IL189258A0 (fr) |
MA (1) | MA29765B1 (fr) |
MX (1) | MX2008002037A (fr) |
NO (1) | NO20080259L (fr) |
NZ (1) | NZ565651A (fr) |
WO (1) | WO2007018463A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006277076B2 (en) | 2005-08-10 | 2012-03-29 | Arne Forsgren Ab | Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
EA201391669A1 (ru) * | 2011-05-11 | 2014-04-30 | Риесбекк Хелткеэр Свиден Аб | Белок f - новый адгезин haemophilus influenzae, способный связывать ламинин и витронектин |
TW201620927A (zh) | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Uspa2蛋白質構築體及其用途 |
BR112019020209A2 (pt) | 2017-03-31 | 2020-06-02 | Glaxosmithkline Intellectual Property Development Limited | Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação. |
WO2018178265A1 (fr) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Composition immunogène, utilisation et procédé de traitement |
BR112020001768A2 (pt) | 2017-08-14 | 2020-09-29 | Glaxosmithkline Biologicals S.A. | método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação. |
MX2021001479A (es) | 2018-08-07 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Novedosos procesos y vacunas. |
CA3148928A1 (fr) | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Procede de preparation d'une composition comprenant un polypeptide de proteine d |
WO2021023691A1 (fr) | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Composition immunogène |
EP4028771A1 (fr) | 2019-09-11 | 2022-07-20 | GlaxoSmithKline Biologicals S.A. | Dosage |
JP2024510717A (ja) | 2021-02-22 | 2024-03-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物、使用及び方法 |
CN114409756B (zh) * | 2022-01-21 | 2023-06-09 | 中国科学院海洋研究所 | 一种牙鲆补体成分C3(PoC3)的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE454403B (sv) * | 1984-05-30 | 1988-05-02 | Alfa Laval Agri Int | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
US5843463A (en) | 1990-12-21 | 1998-12-01 | Antexbiologics, Inc. | Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae |
US6440425B1 (en) * | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
EP0948625B1 (fr) * | 1996-12-20 | 2011-01-26 | The Board Of Regents, The University Of Texas System | Antigenes uspa1 et uspa2 de moraxella catarrhalis |
GB0003502D0 (en) | 2000-02-15 | 2000-04-05 | Smithkline Beecham Sa | Vaccine |
DK2270171T5 (da) | 2000-10-02 | 2013-11-18 | Id Biomedical Corp Quebec | Haemophilus influenzae-antigener og tilsvarende DNA-fragmenter |
SE0102410D0 (sv) | 2001-07-04 | 2001-07-04 | Arne Forsgren | Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis |
CA2452720C (fr) * | 2001-07-26 | 2012-04-17 | Chiron S.R.L. | Vaccins comprenant des adjuvants aluminium et histidine |
GB0222764D0 (en) * | 2002-10-02 | 2002-11-06 | Univ Bristol | Therapeutic peptide |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
AU2006277076B2 (en) * | 2005-08-10 | 2012-03-29 | Arne Forsgren Ab | Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
ZA200805602B (en) | 2006-01-17 | 2009-12-30 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein E; pE) |
-
2006
- 2006-08-08 AU AU2006277076A patent/AU2006277076B2/en not_active Ceased
- 2006-08-08 EA EA200800565A patent/EA014352B1/ru not_active IP Right Cessation
- 2006-08-08 EP EP17196588.2A patent/EP3305807B1/fr active Active
- 2006-08-08 KR KR1020087005428A patent/KR20080042865A/ko not_active Application Discontinuation
- 2006-08-08 CA CA2618554A patent/CA2618554C/fr active Active
- 2006-08-08 US US12/063,408 patent/US8092811B2/en not_active Expired - Fee Related
- 2006-08-08 JP JP2008525959A patent/JP5269594B2/ja not_active Expired - Fee Related
- 2006-08-08 EP EP06769599.9A patent/EP1913019B1/fr not_active Not-in-force
- 2006-08-08 MX MX2008002037A patent/MX2008002037A/es active IP Right Grant
- 2006-08-08 ES ES06769599.9T patent/ES2537274T3/es active Active
- 2006-08-08 NZ NZ565651A patent/NZ565651A/en not_active IP Right Cessation
- 2006-08-08 BR BRPI0614734-8A patent/BRPI0614734A2/pt not_active Application Discontinuation
- 2006-08-08 WO PCT/SE2006/000931 patent/WO2007018463A2/fr active Application Filing
- 2006-08-08 EP EP12189014.9A patent/EP2548884B1/fr active Active
- 2006-08-08 EP EP12189024.8A patent/EP2548885B1/fr not_active Not-in-force
-
2008
- 2008-01-14 NO NO20080259A patent/NO20080259L/no not_active Application Discontinuation
- 2008-02-04 IL IL189258A patent/IL189258A0/en unknown
- 2008-03-07 MA MA30723A patent/MA29765B1/fr unknown
-
2011
- 2011-11-30 IL IL216703A patent/IL216703A0/en unknown
- 2011-12-08 US US13/314,727 patent/US8323667B2/en active Active
-
2012
- 2012-11-01 US US13/666,941 patent/US8895030B2/en active Active
-
2013
- 2013-02-27 JP JP2013036921A patent/JP5763113B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-07 US US14/508,033 patent/US9255127B2/en not_active Expired - Fee Related
-
2015
- 2015-12-31 US US14/986,104 patent/US9657067B2/en active Active
-
2017
- 2017-04-13 US US15/486,513 patent/US10183071B2/en active Active
-
2018
- 2018-12-18 US US16/223,454 patent/US10786562B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29765B1 (fr) | Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire | |
JP7166022B2 (ja) | 治療用変異体アルファ2-マクログロブリン組成物 | |
Riedle et al. | Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/γ-secretase activity | |
ES2717751T3 (es) | Polipéptidos efectores de la subunidad A de la toxina de Shiga resistentes a la escisión por proteasa y moléculas dirigidas a células que los comprenden | |
EA200801571A1 (ru) | Композиции, содержащие молекулы ctl4-ig, и способы их получения | |
TW200740844A (en) | Novel MAdCAM antibodies | |
Metzger et al. | Modular poly (ethylene glycol) matrices for the controlled 3D‐localized osteogenic differentiation of mesenchymal stem cells | |
GB0329825D0 (en) | Biological products | |
Gebhard et al. | MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma | |
EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
WO2008030539A3 (fr) | Méthodes et compositions à base de conjugués toxine diphtérique-interleukine 3 | |
AR065373A1 (es) | Proteinas de fusion de inmunoglobulina y metodos de elaboracion | |
BRPI0520677A2 (pt) | identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina | |
MA30474B1 (fr) | Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee. | |
Williams et al. | Neopetrosiamides, peptides from the marine sponge Neopetrosia sp. that inhibit amoeboid invasion by human tumor cells | |
NO20064134L (no) | Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav | |
Smith et al. | Emerging strategies to access peptide macrocycles from genetically encoded polypeptides | |
TN2009000194A1 (en) | Novel antiproliferation antibodies | |
KR20190087461A (ko) | p53 분해 유도 분자 및 의약 조성물 | |
Kawaguchi et al. | Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking | |
Junk et al. | Total synthesis and configurational revision of mozamide A, a hydroxy-brunsvicamide | |
JP7061800B2 (ja) | Rasタンパク質分解誘導分子及び医薬組成物 | |
Basler et al. | On the role of the immunoproteasome in transplant rejection | |
Zhang et al. | Exploring and exploiting plant cyclic peptides for drug discovery and development | |
Diez-Torrubia et al. | Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues |